Cargando…

Survival Benefit of Supratotal Resection in a Long-term Survivor of IDH-wildtype Glioblastoma: A Case Report and Literature Review

Glioblastoma multiforme (GBM) is an aggressive cancer type, with fewer than 3–5% of patients surviving for more than 3 years. We describe a 48-year-old right-handed man who presented with generalized seizure attacks. Magnetic resonance imaging (MRI) revealed a heterogeneous gadolinium-enhancing lesi...

Descripción completa

Detalles Bibliográficos
Autores principales:	YAMAGUCHI, Junya, MOTOMURA, Kazuya, OHKA, Fumiharu, AOKI, Kosuke, TANAHASHI, Kuniaki, HIRANO, Masaki, CHALISE, Lushun, NISHIKAWA, Tomohide, SHIMIZU, Hiroyuki, NATSUME, Atsushi, WAKABAYASHI, Toshihiko, SAITO, Ryuta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japan Neurosurgical Society 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769439/ https://www.ncbi.nlm.nih.gov/pubmed/35079543 http://dx.doi.org/10.2176/nmccrj.cr.2021-0120

Ejemplares similares

Multiple metastases to the bone and bone marrow from a 1p/19q-codeleted and IDH2-mutant anaplastic oligodendroglioma: a case report and literature review
por: Shimizu, Hiroyuki, et al.
Publicado: (2020)

NQPC-02 Long-term survival in patients with primary intracranial germ cell tumors treated with surgery, platinum-based chemotherapy, and radiotherapy: a single-institution study
por: Motomura, Kazuya, et al.
Publicado: (2020)

STMO-6 Impact of the extent of resection on the survival of patients with lower grade gliomas using awake brain mapping
por: Motomura, Kazuya, et al.
Publicado: (2021)

Supratotal Resection of Gliomas With Awake Brain Mapping: Maximal Tumor Resection Preserving Motor, Language, and Neurocognitive Functions
por: Motomura, Kazuya, et al.
Publicado: (2022)

Imaging features of localized IDH wild-type histologically diffuse astrocytomas: a single-institution case series
por: Kibe, Yuji, et al.
Publicado: (2023)

Next Generation Sequencing-Based Transcriptome Predicts Bevacizumab Efficacy in Combination with Temozolomide in Glioblastoma
por: Adilijiang, Alimu, et al.
Publicado: (2019)

ML-11 Tirabrutinib treatment for recurrent or refractory PCNSL
por: Ohka, Fumiharu, et al.
Publicado: (2021)

MPC-5 Characteristics of H3 G34-mutant gliomas
por: Kibe, Yuji, et al.
Publicado: (2021)

(11)C-methionine- and (18)F-FDG-PET double-negative metastatic brain tumor from lung adenocarcinoma with paradoxical high (18)F-FDG uptake: A case report
por: Tanahashi, Kuniaki, et al.
Publicado: (2022)

TB-03 Newly Established Meningioma Organoid Model Elucidated an Important Role of FOXM1 in Meningioma Progression
por: Yamazaki, Shintaro, et al.
Publicado: (2020)

Mathematical Modeling and Mutational Analysis Reveal Optimal Therapy to Prevent Malignant Transformation in Grade II IDH-Mutant Gliomas
por: Aoki, Kosuke, et al.
Publicado: (2021)

MPC-20 CLINICAL AND MOLECULAR FEATURES OF GLIOBLASTOMAS ARISING IN THE SETTING OF LI FRAUMENI SYNDROME
por: Kibe, Yuji, et al.
Publicado: (2022)

An immuno-wall microdevice exhibits rapid and sensitive detection of IDH1-R132H mutation specific to grade II and III gliomas
por: Yamamichi, Akane, et al.
Publicado: (2016)

CD79B Y196 mutation is a potent predictive marker for favorable response to R‐MPV in primary central nervous system lymphoma
por: Yamaguchi, Junya, et al.
Publicado: (2022)

Navigated repetitive transcranial magnetic stimulation as preoperative assessment in patients with brain tumors
por: Motomura, Kazuya, et al.
Publicado: (2020)

Assessment of Tumor Cells in a Mouse Model of Diffuse Infiltrative Glioma by Raman Spectroscopy
por: Tanahashi, Kuniaki, et al.
Publicado: (2014)

Neurod4 converts endogenous neural stem cells to neurons with synaptic formation after spinal cord injury
por: Fukuoka, Toshiki, et al.
Publicado: (2021)

TB-2 Patient-derived meningioma organoid model demonstrates FOXM1 dependent tumor proliferation
por: Yamazaki, Shintaro, et al.
Publicado: (2021)

Direct intracranial invasion of eccrine spiradenocarcinoma of the scalp: a case report and literature review
por: Kibe, Yuji, et al.
Publicado: (2022)

Current Trends in Targeted Therapies for Glioblastoma Multiforme
por: Ohka, Fumiharu, et al.
Publicado: (2012)

ML-9 TREATMENT OUTCOMES OF TIRABRUTINIB FOR RELAPSED AND REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA IN A SINGLE INSTITUTE
por: Ohka, Fumiharu, et al.
Publicado: (2022)

H3F3A mutant allele specific imbalance in an aggressive subtype of diffuse midline glioma, H3 K27M-mutant
por: Maeda, Sachi, et al.
Publicado: (2020)

Rapid detection of the MYD88 L265P mutation for pre‐ and intra‐operative diagnosis of primary central nervous system lymphoma
por: Yamaguchi, Junya, et al.
Publicado: (2023)

Updates in IDH-Wildtype Glioblastoma
por: Melhem, Jawad M., et al.
Publicado: (2022)

The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma
por: Diplas, Bill H., et al.
Publicado: (2018)

Driver Genetic Mutations in Spinal Cord Gliomas Direct the Degree of Functional Impairment in Tumor-Associated Spinal Cord Injury
por: Nagashima, Yoshitaka, et al.
Publicado: (2021)

STMO-11 Supratotal resection of Glioblastoma with Methionine PET
por: Ko, Ozaki, et al.
Publicado: (2020)

Methylation class oligosarcoma may encompass IDH-wildtype gliomas
por: Ebrahimi, Azadeh, et al.
Publicado: (2022)

PDPN contributes to constructing immunosuppressive microenvironment in IDH wildtype glioma
por: Wang, Xuya, et al.
Publicado: (2022)

Association of hyperglycemia and molecular subclass on survival in IDH-wildtype glioblastoma
por: Liu, Elisa K, et al.
Publicado: (2022)

CBMS-1 Targeting amino acid metabolic vulnerabilities in IDH-mutant and IDH-wildtype gliomas
por: Ohba, Shigeo, et al.
Publicado: (2021)

Double-edged Sword in the Placement of Carmustine (BCNU) Wafers along the Eloquent Area: A Case Report
por: Kuramitsu, Shunichiro, et al.
Publicado: (2014)

Aberrant Transcriptional Regulation of Super-enhancers by RET Finger Protein-histone Deacetylase 1 Complex in Glioblastoma: Chemoresistance to Temozolomide
por: NATSUME, Atsushi, et al.
Publicado: (2019)

Differential Predictors and Clinical Implications Associated With Long-Term Survivors in IDH Wildtype and Mutant Glioblastoma
por: Jiang, Haihui, et al.
Publicado: (2021)

MPC-02 Prognostic effects of molecular factors in elderly patients with IDH-wildtype Glioblastomas
por: Fukai, Junya, et al.
Publicado: (2020)

MPC-1 DNA methylome analysis suggested the presence of “true” IDH-wildtype lower-grade gliomas
por: Satomi, Kaishi, et al.
Publicado: (2021)

The Global DNA Methylation Surrogate LINE-1 Methylation Is Correlated with MGMT Promoter Methylation and Is a Better Prognostic Factor for Glioma
por: Ohka, Fumiharu, et al.
Publicado: (2011)

Estimation of the occurrence rates of IDH1 and IDH2 mutations in gliomas and the reconsideration of IDH-wildtype anaplastic astrocytomas: an institutional experience
por: Cho, Uiju, et al.
Publicado: (2021)

Prognostic Analysis of the IDH1 G105G (rs11554137) SNP in IDH-Wildtype Glioblastoma
por: Saaid, Ayoub, et al.
Publicado: (2022)

GEN-13 FIREWORK PATTERN OF CANCER GENESIS FOR GLIOBLASTOMA, IDH-WILDTYPE
por: Yoon, Seon-Jin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_78e5hcmfhainu1hfcji5hsfkm5